Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients

Published: 19 Jul 2022

Views: 280

Rating:

Save

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Dr Bishal Gyawali speaks to ecancer about the negative results of the PALOMA-2 OS trial.

PAL was the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for ER+/HER2– ABC based on the randomized, phase 2 PALOMA-1 study.

The results of the PALOMA-2 found that cross-line endocrine therapy did not improve overall survival.

The control arm exceeded expectations. The overall survival was 51 months thus meaning the overall improvement in treatments, diagnosis and history of the disease.

Related Videos

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Antibody drug conjugates coming to primetime and new agents for breast cancer

Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA

Antibody drug conjugates coming to primetime and new agents for breast cancer ( Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA )

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer

Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )

Comment: EBCC 2024 highlights

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)

Comment: EBCC 2024 highlights ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy

Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy ( Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium )

SABCS 2023: Highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2023: Highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients

Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )

More from ecancer